Verici Dx PLC Transfer of urine samples to Thermo Fisher
18 Junho 2024 - 3:00AM
RNS Regulatory News
RNS Number : 7733S
Verici Dx PLC
18 June 2024
Verici Dx
plc
("Verici Dx" or the
"Company")
Transfer of urine samples to
Thermo Fisher Scientific
Following completion of the
transfer, full payment has been received
Verici Dx plc (AIM: VRCI), a
developer of advanced clinical diagnostics for organ
transplant, announces it has completed successful transfer of
a portion of the Company's urine samples as
announced as part of the global
commercialisation and licensing agreement announced in November
20231. As previously stated,
it demonstrates the additional value
in the Company's data and sample assets for research.
Sara Barrington, CEO, said:
"We are delighted to announce the
successful completion of this transfer, within the agreed timeline.
This achievement not only highlights our commitment to delivering
on our agreements, but also underscores the substantial value
inherent in the Company's data and sample assets for research
purposes."
Enquiries:
Verici Dx
|
www.vericidx.com
|
Sara Barrington, CEO
|
investors@vericidx.com
|
Julian Baines, Chairman
|
|
|
|
|
|
Singer Capital Markets (Nominated Adviser &
Broker)
|
Tel: +44 20 7496
3000
|
Aubrey Powell / Sam
Butcher
|
|
|
|
Notes
1. Please
refer to RNS number 4652T for further information. A copy of this
announcement can also be found on the company website
https://verici-dx-plc.flint-platform.com/regulatory-news/44270
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a
complementary suite of leading-edge tests forming a kidney
transplant platform for personalised patient and organ response
risk to assist clinicians in medical management for improved
patient outcomes. The underlying technology is based upon
artificial intelligence assisted transcriptomic analysis to provide
RNA signatures focused upon the immune response and other
biological pathway signals critical for transplant prognosis of
risk of injury, rejection and graft failure from pre-transplant to
late stage. The Company also has a mission to accelerate the pace
of innovation by research using the fully characterised data from
the underlying technology, including through collaboration with
medical device, biopharmaceutical and data science
partners.
The foundational research was driven
by a deep understanding of cell-mediated immunity and is enabled by
access to expertly curated collaborative studies in highly
informative cohorts in kidney transplant.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
MSCQDLFFZQLEBBK
Verici Dx (LSE:VRCI)
Gráfico Histórico do Ativo
De Jul 2024 até Ago 2024
Verici Dx (LSE:VRCI)
Gráfico Histórico do Ativo
De Ago 2023 até Ago 2024